NCE-1 Intelligence & Market Opportunity

Ojjaara

Momelotinib

Anticancer

Tablet

Ojjaara is an oral medication for adults with intermediate or high-risk myelofibrosis and anemia. It targets JAK1, JAK2, and ACVR1 to reduce spleen size, relieve symptoms, and improve anemia.

Approval Date

15-Sep-23

NCE-1 Date

15-Sep-27

NCE Date

15-Sep-28

Commercial snapshot

Market performance & projections

Revenue ($M)

730

CAGR (%)

0.1638

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

976

2027

1166

2028

1264

2029

1339

2030

1407

2031

1476

2032

1543

Molecule profile

Details & specifications

Molecule

Momelotinib

Innovator

GLAXOSMITHKLINE LLC

Dosage Form

Tablet

Strength

100 mg, 150 mg and 200 mg

Therapeutic Category

Anticancer

Usage

To treat intermediate or high-risk myelofibrosis in adults with anemia

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.